A bioclinical and chemical aspect, comprising anti-citrullinated peptide antibodies (ACPA), has been incorporated by the 2010 American College of Rheumatology/European League of Rheumatism criteria for RA [8]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.